Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

BACKGROUND: Most patients with ALK- or ROS1-rearranged non-small cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the central nervous system (CNS). This study aimed to determine the safety, efficacy, and pharmacoki...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Lancet Oncol
Main Authors: Shaw, Alice T., Felip, Enriqueta, Bauer, Todd M., Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F., Johnson, Melissa, Dietrich, Jorg, James, Leonard P., Clancy, Jill S., Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777233/
https://ncbi.nlm.nih.gov/pubmed/29074098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30680-0
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker